Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies

Inhibitors of the bromodomain and extraterminal domain family (BETI) have recently entered phase I clinical trials. In patients with advanced leukemia's, potent antileukemia activity was displayed with minimum dose-limiting toxicity. In preclinical models of hematological malignancies, includin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lasorsa, E, Smonksey, M, Kirk, J S, Rosario, S, Hernandez-Ilizaliturri, F J, Ellis, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720887/
https://www.ncbi.nlm.nih.gov/pubmed/26658189
http://dx.doi.org/10.1038/cddis.2015.352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720887/
https://www.ncbi.nlm.nih.gov/pubmed/26658189
http://dx.doi.org/10.1038/cddis.2015.352

Ejemplares similares